[eDisclosure Notice] SK Bioscience Applies for Phase 3 Clinical Trial Plan of COVID-19 Vaccine in Colombia (Afternoon Summary)

[Asia Economy Reporter Minji Lee] SK Bioscience announced on the 29th that it has applied for the Phase 3 clinical trial plan for the double booster shot of the COVID-19 vaccine GBP510 in Colombia.

▲ Geumbi = Announced the decision to dispose of treasury shares worth 532.66 million KRW. This is to expand liquidity through the disposal.

▲ SK Innovation = Announced that its subsidiary BlueOval SK, LLC has decided on a rights offering worth 501.5 billion KRW to raise facility funds.

▲ Hans Biomed = Announced that a shareholders' meeting will be held at the headquarters on the 28th of next month.

▲ Patron = Announced the decision to lend 36.9 billion KRW to its subsidiary Patron VINA. The loan period is until November 30, 2025, and the loan amount corresponds to 7.7% of the total equity capital.

▲ Geosoft = Announced that it has changed its business location to 50 Jongno 1-gil, Jongno-gu, Seoul to improve the management environment and work efficiency.